Omnicell Management

Management criteria checks 2/4

Omnicell's CEO is Randy Lipps, appointed in Sep 1992, has a tenure of 31.58 years. total yearly compensation is $11.02M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth €9.27M. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.

Key information

Randy Lipps

Chief executive officer

US$11.0m

Total compensation

CEO salary percentage	7.4%
CEO tenure	31.6yrs
CEO ownership	0.8%
Management average tenure	2.3yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Randy Lipps's remuneration changed compared to Omnicell's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$11m	US$813k	-US$20m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$8m	US$804k	US$6m
Sep 30 2022	n/a	n/a	US$48m
Jun 30 2022	n/a	n/a	US$61m
Mar 31 2022	n/a	n/a	US$72m
Dec 31 2021	US$8m	US$768k	US$78m
Sep 30 2021	n/a	n/a	US$80m
Jun 30 2021	n/a	n/a	US$60m
Mar 31 2021	n/a	n/a	US$35m
Dec 31 2020	US$8m	US$721k	US$32m
Sep 30 2020	n/a	n/a	US$38m
Jun 30 2020	n/a	n/a	US$49m
Mar 31 2020	n/a	n/a	US$69m
Dec 31 2019	US$7m	US$711k	US$61m
Sep 30 2019	n/a	n/a	US$54m
Jun 30 2019	n/a	n/a	US$48m
Mar 31 2019	n/a	n/a	US$38m
Dec 31 2018	US$6m	US$690k	US$38m
Sep 30 2018	n/a	n/a	US$54m
Jun 30 2018	n/a	n/a	US$48m
Mar 31 2018	n/a	n/a	US$44m
Dec 31 2017	US$5m	US$669k	US$31m

Compensation vs Market: Randy's total compensation ($USD11.02M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Randy's compensation has increased whilst the company is unprofitable.

CEO

Randy Lipps (66 yo)

31.6yrs

Tenure

US$11,022,072

Compensation

Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps had been Executive Chairman and Exec...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Randall Lipps	Founder	31.6yrs	US$11.02m	0.77% $ 9.3m
Nchacha Etta	Executive VP & CFO	less than a year	US$5.16m	0.00032% $ 3.8k
Corey Manley	Executive VP	2.8yrs	US$3.06m	0.0083% $ 98.8k
Minoo Mortazavi	Senior Vice President of Global Operations	less than a year	no data	no data
Brian Nutt	VP, Chief Accounting Officer & Corporate Controller	less than a year	no data	no data
Giri Chodavarapu	Senior VP & Chief Information Officer	4.6yrs	no data	no data
Kathleen Nemeth	Senior Vice President of Investor Relations	no data	no data	no data
Maximo Rocha	Senior VP & Chief People Officer	less than a year	no data	no data
Joseph Spears	Executive Adviser	less than a year	no data	0.032% $ 384.3k
Sara Dalmasso	Senior VP & GM of International	2.3yrs	no data	no data
David Vanella	Senior Vice President of Quality & Product Regulatory	2.3yrs	no data	no data
Vicki MacDevitt	Chief of Staff	6.8yrs	no data	no data

2.3yrs

Average Tenure

53yo

Average Age

Experienced Management: OC9's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Randall Lipps	Founder	31.6yrs	US$11.02m	0.77% $ 9.3m
Eileen Voynick	Independent Director	less than a year	no data	0.0053% $ 63.1k
Mark Parrish	Independent Director	11.3yrs	US$328.81k	0.13% $ 1.6m
Sara White	Director Emeritus	less than a year	US$286.45k	0% $ 0
Robin Seim	Independent Director	5.1yrs	US$282.54k	0.069% $ 824.9k
Joanne Bauer	Lead Independent Director	10.3yrs	US$341.69k	0.061% $ 731.7k
Edward Bousa	Independent Director	2.8yrs	US$266.45k	0.0068% $ 81.8k
Vance Moore	Independent Director	11.9yrs	US$284.30k	0.15% $ 1.8m
Bruce Scott	Independent Director	4.9yrs	US$267.79k	0.016% $ 188.7k
Mary Garrett	Independent Director	1.9yrs	US$279.13k	0.0033% $ 39.3k
Kaushik Ghoshal	Independent Director	less than a year	US$173.92k	0% $ 0

4.9yrs

Average Tenure

66yo

Average Age

Experienced Board: OC9's board of directors are considered experienced (4.9 years average tenure).

Omnicell Management

Management criteria checks 2/4

Key information

Recent management updates

Omnicell, Inc., Annual General Meeting, May 21, 2024

Omnicell, Inc. Announces Executive Changes

High number of new directors

Omnicell, Inc. Announces Board Changes

Omnicell, Inc. Announces Board Changes

Omnicell, Inc. Appoints Bobby Ghoshal to Board of Directors

Recent updates

Omnicell, Inc. Announces XT Amplify

Omnicell, Inc. to Report Q1, 2024 Results on May 02, 2024

Omnicell, Inc., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: US$0.45 loss per share (vs US$0.13 profit in FY 2022)

New minor risk - Shareholder dilution

Omnicell, Inc. Announces Executive Changes

High number of new directors

New minor risk - Share price stability

Full year 2023 earnings released: US$0.45 loss per share (vs US$0.13 profit in FY 2022)

Omnicell, Inc. Reports Unaudited Impairment Changes Results for the Fourth Quarter Ended December 31, 2023

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Fiscal Year 2024

Omnicell, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Omnicell, Inc. Announces Board Changes

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.12 (vs US$0.38 in 3Q 2022)

Omnicell, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Omnicell, Inc. Announces Board Changes

New minor risk - Shareholder dilution

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.076 (vs US$0.20 in 2Q 2022)

Omnicell, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Omnicell, Inc. Appoints Bobby Ghoshal to Board of Directors

Founder recently bought €274k worth of stock

Omnicell Announces Leadership and Organizational Changes

First quarter 2023 earnings released: US$0.33 loss per share (vs US$0.19 profit in 1Q 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: US$0.13 (vs US$1.79 in FY 2021)

Omnicell, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Omnicell, Inc. to Showcase Advanced Services Designed to Deliver Enhanced Medication Management Outcomes at ASHP Midyear 2022

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.38 (vs US$0.67 in 3Q 2021)

Omnicell, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Omnicell, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$0.20 (vs US$0.47 in 2Q 2021)

Omnicell, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Omnicell, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Omnicell, Inc. Elects Mary Garrett as Class III Director

Omnicell, Inc. Elects Mary Garrett as Class III Director

First quarter 2022 earnings released: EPS: US$0.19 (vs US$0.33 in 1Q 2021)

Omnicell, Inc. Announces Board Retirements

Omnicell, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Omnicell, Inc. Announces Retirement of Jim Judson and Bruce Smith from Board of Directors

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Now 20% undervalued

Omnicell, Inc. (NasdaqGS:OMCL) acquired MarkeTouch Media, Inc. for $82 million.

Omnicell, Inc. (NasdaqGS:OMCL) completed the acquisition of ReCept Holdings Inc.

Senior VP recently sold €1.3m worth of stock

Omnicell, Inc. (NasdaqGS:OMCL) entered into a definitive agreement to acquire ReCept Holdings Inc. for $100 million.

Third quarter 2021 earnings released: EPS US$0.67 (vs US$0.21 in 3Q 2020)

Lead Independent Director recently sold €650k worth of stock

Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology-Enabled Services with Summer 2021 Release

Executive VP & CFO recently sold €800k worth of stock

Second quarter 2021 earnings released: EPS US$0.47 (vs US$0.10 loss in 2Q 2020)

Executive VP & CFO recently sold €266k worth of stock

First quarter 2021 earnings released: EPS US$0.33 (vs US$0.27 in 1Q 2020)

Omnicell, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2021

New 90-day high: €114

The Christ Hospital Health Network Selects Omnicell’s Central Pharmacy Dispensing Service to Enhance Medication Inventory Management

Full year 2020 earnings released: EPS US$0.76 (vs US$1.48 in FY 2019)

Revenue beats expectations

Omnicell, Inc. Appoints Christine Mellon as Executive Vice President and Chief People Officer

Executive VP of Marketing, Strategy & Business Development has left the company

Full year 2020 earnings released: EPS US$0.76 (vs US$1.48 in FY 2019)

Revenue beats expectations

Omnicell, Inc. Announces Resignation of Nhat H. Ngo as Executive Vice President, Marketing, Strategy & Business Development, Effective February 15, 2021

WVU Medicine Selects Omnicell One Intelligence Solution to Drive Better Pharmacy Inventory Management, Optimize Costs, and Support Better Patient Care